Glenmark Pharmaceuticals' (NSE:GLENMARK, BOM:532296) US-based arm Glenmark Pharmaceuticals Inc has launched its drug Clindamycin Phosphate Foam, 1%, according to a Wednesday filing to the Indian stock exchanges.
Glenmark's Clindamycin Phosphate Foam, 1%, is bioequivalent and therapeutically equivalent to Mylan Pharmaceuticals' reference listed drug Evoclin Foam, 1%.
Clindamycin Phosphate Foam is a topical treatment for acne, according to the company website.
Shares of the company were down over 2% in recent trade.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。